Solid-state 13C NMR study of indomethacin polymorphism
Authors:
- Katsuhiko MasudaKMKatsuhiko Masuda
- Sachio TabataSTSachio Tabata
- Hiroyuki KonoHKHiroyuki Kono
- Yasuyuki SakataYSYasuyuki Sakata
- Tetsuo HayaseTHTetsuo Hayase
- Etsuo YonemochiEtsuo Yonemochi
- Katsuhide TeradaKTKatsuhide Terada
- 1 August 2006
- journal article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 318 (1-2) , 146-153
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs)Advanced Drug Delivery Reviews, 2004
- General principles of pharmaceutical solid polymorphism A supramolecular perspectiveAdvanced Drug Delivery Reviews, 2004
- Reactivity Differences of Indomethacin Solid Forms with Ammonia GasJournal of the American Chemical Society, 2002
- Characterization of the solid-state: spectroscopic techniquesAdvanced Drug Delivery Reviews, 2001
- Crystal nucleation and growth of indomethacin polymorphs from the amorphous stateJournal of Non-Crystalline Solids, 2000
- Pharmaceutical Solids: A Strategic Approach to Regulatory ConsiderationsPharmaceutical Research, 1995
- Isolation and Solid‐State Characteristics of a New Crystal Form of IndomethacinJournal of Pharmaceutical Sciences, 1992
- Physicochemical characterization of indomethacin polymorphs and the transformation kinetics in ethanol.Chemical and Pharmaceutical Bulletin, 1985
- Crystal and molecular structure of an antiinflammatory agent, indomethacin, 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acidJournal of the American Chemical Society, 1972
- Pharmaceutical Applications of PolymorphismJournal of Pharmaceutical Sciences, 1969